Newamsterdam Pharma Company N.V. ( (NAMS) ) has released its Q3 earnings. Here is a breakdown of the information Newamsterdam Pharma Company N.V. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company based in the Netherlands, focusing on developing therapies for cardiometabolic diseases, particularly those involving cholesterol management. The company recently released its earnings report for the third quarter of 2025, highlighting its ongoing efforts in the development of its lead product candidate, obicetrapib, a CETP inhibitor aimed at lowering LDL cholesterol levels. Despite a net loss of $72 million for the quarter, NewAmsterdam Pharma reported revenues of $348,000, primarily from supply agreements, and continued to invest heavily in research and development, with expenses reaching $31 million. The company also noted a decrease in cash and cash equivalents from $771 million at the end of 2024 to $539 million by September 2025, reflecting its significant investment in product development and operational activities. Looking forward, NewAmsterdam Pharma remains committed to advancing its clinical trials and exploring new market opportunities for obicetrapib, with management expressing optimism about the potential for regulatory approvals and future revenue growth.